Actos Sales Data
Last updated: February 2014 (updated quarterly).
The following data shows Actos U.S. retail sales in Q4 2013 compared to previous quarters.
|Date Range||Sales Rank||Sales ($000)||Units (000)|
|Q3 2012||39 (18)||$333,494||-41.96%||929||-46.64%|
|Q1 2012||21 (3)||$630,970||-4.52%||1,912||-12.97%|
|Q4 2011||18 (3)||$660,834||-15.22%||2,197||-19.67%|
|Q3 2011||15 (6)||$779,504||-11.05%||2,735||-12.03%|
* Units refer to the number of packages sold.
|September 27, 2013||Takeda Responds to Verdict in Diabetes Drug Case|
|June 16, 2011||Diabetes Drug Actos May Raise Risk for Bladder Cancer: FDA|
|June 16, 2011||Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer|
|June 16, 2011||Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of Actos (pioglitazone HCl)|
|September 20, 2010||US Agency Probes Risks Of Bladder Cancer With Diabetes Pill Actos, Rival To Glaxo's Avandia|
|February 15, 2010||Diabetes Drugs Avandia, Actos Tied to Fractures in Women|
|August 18, 2009||Avandia Raises Heart Failure Risk More Than Actos|
|December 10, 2008||2 Diabetes Drugs Double Fracture Risk in Women|
|December 10, 2008||Popular Class of Diabetes Drugs Doubles Risk of Fractures in Women|
|November 24, 2008||Avandia's Heart Risk Higher Than Others in Its Class|